Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Gainesville, Florida Clear all
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00553462
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, erlotinib hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
99
States / cities
Castro Valley, California • Fremont, California • Martinez, California + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer

NCT00005088
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
239
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 182 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 23, 2026, 8:15 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT00990327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Long Term Open Label Continuation Study

NCT00195650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT03816891
View directory record Official record
Conditions
Prurigo Nodularis, Pruritis
Interventions
Vixarelimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury

NCT02276079
View directory record Official record
Conditions
Brain Concussion
Interventions
Aerobic Exercise, Non-Aerobic Exercise
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jul 23, 2026, 8:15 AM EDT
Withdrawn Phase 2 Interventional

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

NCT02269579
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

NCT02097589
View directory record Official record
Conditions
Healthy Controls
Interventions
Atorvastatin, Pneumovax 23, Placebo (lactose pill)
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

NCT02733042
View directory record Official record
Conditions
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Durvalumab, Lenalidomide, Rituximab, Ibrutinib, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 23, 2026, 8:15 AM EDT
Recruiting No phase listed Observational

The Study of Urinary Biomarkers in Patients With Hypomagnesemia

NCT07056283
View directory record Official record
Conditions
Hypomagnesemia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

NCT00082082
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Thymalfasin (thymosin alpha-1), Trans arterial chemoembolization (TACE)
Drug · Procedure
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Gainesville, Florida • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jul 23, 2026, 8:15 AM EDT
Terminated Phase 3 Interventional

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

NCT00282503
View directory record Official record
Conditions
Acute Graft-versus-Host Disease
Interventions
Methoxsalen+ECP, Methylprednisolone, Ecp
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

NCT00072046
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab, recombinant interferon alfa
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
489
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 341 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006388
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

rTMS for Motor and Mood Symptoms of Parkinson's Disease

NCT01080794
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

NCT03921541
View directory record Official record
Conditions
Arginase I Deficiency, Hyperargininemia
Interventions
Pegzilarginase, Placebo
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
17
States / cities
Rogers, Arkansas • Orange, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 23, 2026, 8:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reference Range Study for the Quantra System With the QStat Cartridge in Obstetric Patients

NCT06415760
View directory record Official record
Conditions
Obstetric Hemostasis, Coagulation
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • Raleigh, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jul 23, 2026, 8:15 AM EDT
Completed No phase listed Observational

Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain

NCT01390103
View directory record Official record
Conditions
Hip Pain
Interventions
Assessment following hip injection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Jul 23, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Prevention of Dichloroacetate Toxicity

NCT00031161
View directory record Official record
Conditions
Acidosis, Lactic, Chronic Disease
Interventions
Nitisinone (NTBC), Dichloroacetate, Low-tyrosin diet
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 8:15 AM EDT
Active, not recruiting No phase listed Observational

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

NCT03045029
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Fresno, California • Los Angeles, California • San Juan Capistrano, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 8:15 AM EDT